Aurobindo Pharma on Tuesday said its auxiliary CuraTeQ Biologics has extended the extent of its marketing and dissemination concurrence with Orion Corporation (Orion) to popularize its biosimilars pipeline to remember the Baltic states for Europe. Prior in 2020, CuraTeQ and Orion had gone into a licensing agreement, granting marketing and distribution rights for Indian company’s biosimilar items under development in the Nordic states, Austria, Hungary and Slovenia.
CuraTeQ filed its first oncology biosimilar product with the European Medicines Agency (EMA) in September 2021 and filed its second biosimilar product, also in the oncology segment on January 10, 2022.
Under the terms of the agreement, Orion will be responsible for commercialization of CuraTeQ’s biosimilar products, currently in various stages of development/filing for the partnered territories, Aurobindo Pharma said in regulatory filing.
“We remain committed to expand the reach of our affordable, high quality products to patients globally and the strengthening of partnership with Orion provides our biosimilar products a pan-Europe access. We are encouraged with our progress on biosimilars development and look forward to execution of the same in the coming years,” Aurobindo Pharma Vice Chairman & Managing Director Nithyananda Reddy stated.
“Orion’s understanding of the biosimilars adoption along with extensive commercial infrastructure in the NORDICS and other territories in the EEA make it an ideal partner to expand the accessibility of our biosimilar products in selected markets of Europe, complementing our group’s wide footprint in other European markets, he stated.
CuraTeQ CEO Satakarni Makkapati said Orion has a demonstrated and proven track record of successfully commercialising biosimilars in the Nordic and Baltic states in Europe.
Orion Corporation SVP Specialty Products Virve Laitinen said the agreement will strengthen the company’s position as one of the leading generics providers in the Nordics and Baltics.
Check the latest news about business news section for best information.